euglena Co., Ltd. (JP:2931) has released an update.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Euglena Co., Ltd. saw a 3.5% rise in sales in the third quarter of FY2024, driven by a strong performance in the healthcare sector. Despite a decline in the biofuel business, the company’s adjusted EBITDA surged by 64%, indicating a potential for profitability by the end of the year. Strategic investments and partnerships are poised to support further growth and market expansion.
For further insights into JP:2931 stock, check out TipRanks’ Stock Analysis page.